Favorable outcomes from allogeneic and autologous stem cell transplantation for patients with transformed nonfollicular indolent lymphoma

Biology of Blood and Marrow Transplantation

Volumn 20, Issue 11, 2014, Pages 1813-1818

  Villa, Diego ^a,b   George, Anupkumar ^c   Seymour, John F ^c   Toze, Cynthia L ^d   Crump, Michael ^a   Lee, Christina ^e   Buckstein, Rena ^e   Stewart, Douglas A ^f   MacDonald, David ^g   Foley, Ronan ^h   Xenocostas, Anargyros ⁱ   Sabloff, Mitchell ^j   Chua, Neil ^k   Couture, Felix ^l   Larouche, Jean F ^l   Cohen, Sandra ^m   Savage, Kerry J ^b   Connors, Joseph M ^b   Panzarella, Tony ⁿ   Carney, Dennis A ^c   Dickinson, Michael ^c   Kuruvilla, John ^a   more..

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f TOM BAKER CANCER CENTRE   (Canada)

^g QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^h HAMILTON HEALTH SCIENCES   (Canada)

ⁱ LONDON HEALTH SCIENCES CENTRE   (Canada)

^j UNIVERSITY OF OTTAWA   (Canada)

^k CROSS CANCER INSTITUTE   (Canada)

^l LAVAL UNIVERSITY   (Canada)

^m MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

ⁿ UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

Allogeneic transplant; Autologous transplant; Rituximab; Transformed lymphoma

Indexed keywords

ANTHRACYCLINE; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; FEMALE; FOLLICULAR LYMPHOMA; HISTOLOGY; HUMAN; LYMPHOCYTOMA; MALE; MARGINAL ZONE LYMPHOMA; MIDDLE AGED; MYELOABLATIVE CONDITIONING; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; STEM CELL TRANSPLANTATION; WALDENSTROEM MACROGLOBULINEMIA; YOUNG ADULT; AGED; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOMA, B-CELL; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PROCEDURES; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 84908028953     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.07.015     Document Type: Article

References (33)

1. Al-Tourah A.J., Gill K.K., Chhanabhai M., et al. Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. JClin Oncol 2008, 26:5165-5169.
2. Bastion Y., Sebban C., Berger F., et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. JClin Oncol 1997, 15:1587-1594.
3. Conconi A., Ponzio C., Lobetti-Bodoni C., et al. Incidence, risk factors and outcome of histological transformation in follicular lymphoma. Br J Haematol 2012, 157:188-196.
4. Montoto S., Davies A.J., Matthews J., et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. JClin Oncol 2007, 25:2426-2433.
5. Dungarwalla M., Appiah-Cubi S., Kulkarni S., et al. High-grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis. Br J Haematol 2008, 143:71-74.
6. Robertson L.E., Pugh W., O'Brien S., et al. Richter's syndrome: a report on 39 patients. JClin Oncol 1993, 11:1985-1989.
7. Sretenovic M., Colovic M., Jankovic G., et al. More than a third of non-gastric malt lymphomas are disseminated at diagnosis: a single center survey. Eur J Haematol 2009, 82:373-380.
8. Zucca E., Conconi A., Pedrinis E., et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 2003, 101:2489-2495.
9. Andreadis C., Schuster S.J., Chong E.A., et al. Long-term event-free survivors after high-dose therapy and autologous stem-cell transplantation for low-grade follicular lymphoma. Bone Marrow Transplant 2005, 36:955-961.
10. Chen C.I., Crump M., Tsang R., et al. Autotransplants for histologically transformed follicular non-Hodgkin's lymphoma. Br J Haematol 2001, 113:202-208.
11. Foran J.M., Apostolidis J., Papamichael D., et al. High-dose therapy with autologous haematopoietic support in patients with transformed follicular lymphoma: a study of 27 patients from a single centre. Ann Oncol 1998, 9:865-869.
12. Sabloff M., Atkins H.L., Bence-Bruckler I., et al. A15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Biol Blood Marrow Transplant 2007, 13:956-964.
13. Thomson K.J., Morris E.C., Bloor A., et al. Favorable long-term survival after reduced-intensity allogeneic transplantation for multiple-relapse aggressive non-Hodgkin's lymphoma. JClin Oncol 2009, 27:426-432.
14. Villa D., Crump M., Panzarella T., et al. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group. JClin Oncol 2013, 31:1164-1171.
15. Williams C.D., Harrison C.N., Lister T.A., et al. High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry. JClin Oncol 2001, 19:727-735.
16. Wirk B., Fenske T.S., Hamadani M., et al. Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma. Biol Blood Marrow Transplant 2014, 20:951-959.
17. Ban-Hoefen M., Kelly J.L., Bernstein S.H., et al. High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era. Leuk Lymph 2012, 53:830-835.
18. Ban-Hoefen M., Vanderplas A., Crosby-Thompson A.L., et al. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. Br J Haematol 2013, 163:487-495.
19. Eide M.B., Lauritzsen G.F., Kvalheim G., et al. High dose chemotherapy with autologous stem cell support for patients with histologically transformed B-cell non-Hodgkin lymphomas. A Norwegian multi centre phase II study. Br J Haematol 2011, 152:600-610.
20. Friedberg J.W., Neuberg D., Gribben J.G., et al. Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. Biol Blood Marrow Transplant 1999, 5:262-268.
21. Kuruvilla J., Chen B., MacDonald D.A., et al. Salvage chemotherapy (SC) and autologous stem cell transplantation (ASCT) for transformed indolent lymphoma (TR): A subgroup analysis of NCIC CTG LY12. Hematol Oncol 2013, 31(Suppl 1). Abstr 64.
22. Ramadan K.M., Connors J.M., Al-Tourah A.J., et al. Allogeneic SCT for relapsed composite and transformed lymphoma using related and unrelated donors: long-term results. Bone Marrow Transplant 2008, 42:601-608.
23. Ramadan K.M., Connors J.M., Al-Tourah A., et al. Autologous stem cell transplantation is superior to myeloablative allogeneic SCT as a salvage therapy for patients with refractory/relapsed transformed lymphoma. Blood 2008, 112:4459.
24. Rezvani A.R., Storer B., Maris M., et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in relapsed, refractory, and transformed indolent non-Hodgkin's lymphoma. JClin Oncol 2008, 26:211-217.
25. Villa D., Crump M., Keating A., et al. Outcome of patients with transformed indolent non-Hodgkin lymphoma referred for autologous stem-cell transplantation. Ann Oncol 2013, 24:1603-1609.
26. Cwynarski K., van Biezen A., de Wreede L., et al. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome): A retrospective analysis from the Chronic Lymphocytic Leukemia Subcommittee of the Chronic Leukemia Working Party and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. JClin Oncol 2012, 30:2211-2217.
27. Rodriguez J., Keating M.J., O'Brien S., et al. Allogeneic haematopoietic transplantation for Richter's syndrome. Br J Haematol 2000, 110:897-899.
28. Tsimberidou A.M., O'Brien S., Khouri I., et al. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. JClin Oncol 2006, 24:2343-2351.
29. Cheson B.D., Horning S.J., Coiffier B., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. JClin Oncol 1999, 17:1244.
30. Kaplan E., Meier P. Nonparametric estimation from incomplete observations. JAm Stat Assoc 1958, 53:457-481.
31. Bains P., Al Tourah A., Campbell B.A., et al. Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy. Ann Oncol 2013, 24:428-432.
32. Al-Tourah A.J., Savage K.J., Gill K.K., et al. Addition of rituximab to CHOP chemotherapy significantly improves survival of patients with transformed lymphoma. Blood 2007, 110:790.
33. Tan D., Rosenberg S.A., Lavori P., et al. Improved prognosis after histologic transformation (HT) of follicular lymphoma: the Stanford experience 1960-2003. Ann Oncol 2008, 19(Suppl 4). iv111.